A new breath test will now help in identifying and differentiating between the types of lung cancer in humans with high accuracy, a new study has suggested.
Metabolomx, a diagnostic company focused on the detection of the metabolomics signature of cancer from exhaled breath.
This seminal study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, used Metabolomx’ first-generation colorimetric sensor array, and reported accuracy exceeding 80 per cent in lung cancer detection, comparable to computerized tomography (CT) scan.
Further, the study found that Metabolomx’ first-generation colorimetric sensor array could identify the subtype of lung cancer (small cell versus adenocarcinoma versus squamous cell) with accuracy approaching 90 per cent.
“Our research shows that breath testing may help identify patients with lung cancer, as well as provide us with information that can help with treatment decisions, such as the type of lung cancer, its stage, and prognosis,” Dr Mazzone said.
No comments:
Post a Comment